Interview with Esther Lim, Managing Partner, Finnegan
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Address: Mirae Asset Tower 28/F, Unit A-B No. 166 Lujiazui Ring Road, Pudong Shanghai, China 200120,China
Tel: 86 21 6194 2000
Web: http://www.finnegan.com/en-US/locations/region.aspx?region=5
Finnegan has more than 40 years of experience in successfully navigating U.S. IP law. Finnegan works with clients of all sizes, from virtually every industry and technology to identify, protect, advocate, and leverage their most valuable IP assets. Finnegan guides U.S. organizations as well as multinational entities that wish to conduct business in the U.S. Foreign innovators entering the U.S. market are often surprised at the intricacies of the intellectual property legal system. Patent law is becoming increasingly complex, with regulatory and legislative changes having a dramatic impact on companies’ intellectual property and business strategies. Finnegan views this complexity as an opportunity to think creatively. Finnegan’s full range of IP experience—from idea protection and management to litigation and appeals—gives the company the perspective to anticipate potential issues and devise creative solutions.
Asia boasts some of the world’s most sophisticated markets and fastest growing economies. Innovative corporations and organizations across Asia turn to Finnegan to identify, protect, advocate, and leverage their most valuable IP assets. To meet the needs of Finnegan’s Asian clients conducting business in their headquarter countries or in the United States, Finnegan has established offices in Shanghai, Taipei, and Tokyo. The firm also has strong ties to the IP legal communities in Korea and India, and our attorneys regularly travel to these countries to speak at conferences and meet with clients.
Finnegan’s licensed Foreign Representative Office in China is located in the Pudong area of Shanghai, and Finnegan’s attorneys are able to serve clients anywhere in the greater China region. As Chinese companies continue to expand their markets, Finnegan is on the ground to assist them with their U.S. IP strategies and needs.
Finnegan is proud to have been active and involved in the Chinese community for many years. We have over 30 professionals who speak Chinese, many with degrees from Chinese universities. Our local outreach efforts have included seminars, educational programs, and roundtable discussions for both business groups and universities. We are particularly active in U.S. IP licensing matters in China.
Intellectual Property Law
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic significance of the market as one of the…
Multinational pharma companies have been setting up shop in China ever since Novartis launched its Chinese affiliate in 1987, with other pharma giants following in its footsteps soon after, eager…
Gaobo Zhou is Partner and co-leader of the Healthcare Practice in China and has been with McKinsey for over a decade, Gaobo discusses the changes occurring within the complex and…
“Mental health is currently a major problem in China, and will become an ever greater problem unless effective interventions are put in place.” Mental Health has Long Been a…
Pius Hornstein, Country Chair of Sanofi China appointed in March 2019, shares his initial impressions on the fast-changing Chinese market; his mandate to drive a transformation of the organization in…
HE Ming, founder and CEO of Sino-American (Suzhou) Pharmaceutical Services (SAPS), shares his commitment to bringing international quality standards to the Chinese pharma industry, the comprehensive portfolio of quality management,…
Dr Shuqian Jing, founder, Chairman and CEO of Gmax Biopharm, an innovative biotech company headquartered in Hangzhou, shares how his experiences at global biopharma companies like BMS and Amgen inspired…
Serial entrepreneur and Ronnsi CEO Yiming Yao discusses the inspiration behind the company’s formation, its unique specialization in ovine heparin, and his strategy to take the firm to the next…
China’s rapidly-growing biotech sector is increasingly hungry for preclinical drug candidates to commercialise in China, and Chinese companies are spending top dollar for cutting-edge technology from the US and UK.…
Dr Dafang Zhong, director of Shanghai Center for Drug Metabolism and Pharmacokinetics Research at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, shares his professional career within the…
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions…
See our Cookie Privacy Policy Here
